Status:
COMPLETED
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Lead Sponsor:
UCB Pharma
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Detailed Description
This is a Phase IIIB, multi-centre, open-label, follow-up study to study C87076 \[NCT00674362\] designed to continue to assess the safety and efficacy of Certolizumab Pegol. Two different population ...
Eligibility Criteria
Inclusion
- Patients with established adult rheumatoid arthritis on Disease Modifying Anti-Rheumatic Drugs (DMARDs) therapy who were included in C87076 protocol and:
- either failed to achieve remission after 6 months of study treatment
- or flared after the 6 months of study treatment and completed the study (C87076 \[NCT00674362\])
Exclusion
- All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00843778
Start Date
January 1 2009
End Date
December 1 2012
Last Update
January 30 2014
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
6
Vienna, Austria
2
11
Rennes, France
3
64
Toulouse, France
4
10
Tours, France